Table 1. Baseline characteristics prior to high-dose testosterone patients (n = 33).

Race	n (%)
Caucasian	29 (88)
African-American	3 (9)
Other	1 (3)
Median Age	n (range)
Treatment	73 (60–88)
ECOG PS	n (%)
0–1	24 (73)
2	1 (3)
Unknown	8 (24)
Gleason Score	n (%)
6–7	16 (48)
8–10	15 (46)
Unknown	2 (6)
Metastatic Disease	n (%)
Bone Only	20 (61)
Lymph Node	12 (36)
Soft Tissue	1 (3)
Lab Values	n (range)
PSA	29.3 (0.04–845)
Hemoglobin	12 (8.3–14.7)
ALP	99 (37–541)
LDH	196 (91–871)
Baseline Nadir Testosterone	272 (60–1374)
Previous CRPC Therapies
Median	2 (1–10)
Abiraterone	25 (76)
Enzalutamide	21 (64)
Radium-223	8 (24)
Taxanes	11 (33)
Immunotherapy	8 (24)
Oral Antiandrogen Treatment Prior to HDT	n (%)
Abiraterone	16 (48)
Enzalutamide	7 (21)
Sequential Abi and Enza	6 (18)